Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
As official media partners, VJHemOnc is thrilled to present updates from the 46th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT).
This year's meeting shed light on the latest research and education in hematological transplantation and cellular therapies.
#ASH23 a great opportunity to discuss with colleagues from #Armenia about the development of clinical research in hematology in Yerevan @NersesGH Prof. Y. Hakobyan #ArmenianHematologyAssociation
#ASH23 HOVON analysis of dynamic frailty in #MMsm - building on work by @HiraSMian @tanyawildes et al.
Some pts get less frail with myeloma treatment 👏
Also note that, of pts who become “frailer,” some of this is artifactual because IMWG model de facto penalizes older age.
Great chatting with @tarekmd91 (@IcahnMountSinai) who gave an overview of updates on the use of #CART in #MultipleMyeloma
@ASH_hematology #Myeloma #MMsm #HemOnc
#ASH23 | We spoke with @NersesGH from Yeolyan Hematology and Oncology Center on challenges that remain in the diagnosis and treatment of #BPDCN
Head to poster number 1861 at #ASH23 at 5:30 pm to learn more!
Explore all the practice-changing transplant updates presented at EBMT 2020 including conditioning, relapse risk factors and the impact of the microbiome!
CAR-T & Cellular Therapy
CAR-T has rapidly entered the treatment landscape of a vast number of hematological malignancies. Get the latest here!